ASCENDIS PHARMA BONE DISEASES A/S: Financial statements 2022
CVR: 32323596
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ASCENDIS PHARMA BONE DISEASES A/S (CVR 32323596) has filed annual accounts for 2022. In 2022, the company reported a gross profit of EUR -66,598,343 and a net result of EUR -72,197,542 compared with EUR -61,825,261 the year before. Equity in the 2022 report amounted to EUR -249,169,766.
- Gross Profit
- EUR -66,598,343
- Profit/Loss
- EUR -72,197,542
- Equity
- EUR -249,169,766
- Total Assets
- EUR 18,541,393
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -66.6M EUR | -72.2M EUR | -249.2M EUR | 0 |
| 2021 | - | -58M EUR | -61.8M EUR | -177M EUR | 0 |
| 2020 | - | -38.8M EUR | -41.3M EUR | -115.1M EUR | 0 |
| 2019 | - | -27.5M EUR | -28.8M EUR | -73.8M EUR | 0 |
| 2018 | - | -18.9M EUR | -19.8M EUR | -45M EUR | 0 |
Official annual report
Keep an eye on ASCENDIS PHARMA BONE DISEASES A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2021. Gross profit came to DKK -57,981,885, and the net result was DKK -61,825,261.
About ASCENDIS PHARMA BONE DISEASES A/S
ASCENDIS PHARMA BONE DISEASES A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S and ASCENDIS PHARMA RHEUMATOLOGY DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 229,581,000 and a net result of EUR 134,982,000 compared with EUR -139,088 the year before. Equity in the 2025 report amounted to EUR -372,183,000.